icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
Bortezomib, cyclophosphamide and dexamethasone (VCD) is the current standard of care in Australia for the initial treatment of transplant ineligible multiple myeloma patients.

Daratumumab is a monoclonal antibody which has shown a favourable safety profile and promising efficacy in monotherapy and combination therapy trials however none of these use Daratumumab with VCD therapy. Our trial is to assess whether adding Daratumumab to VCD improves patient progression free survival rates.

Recruitment updated as of April 2019.

STUDY DESIGN

Multicentre, open label, randomised phase 2 study

CORRELATIVE STUDIES

Samples of blood and bone marrow are collected for additional studies into natural killer cell response to therapy and biomarker analysis

TRIAL PRINCIPAL INVESTIGATOR

Associate Professor Peter Mollee

TIME FRAME

2017 – 2021

SITE LOCATIONS

  • Canberra Hospital, ACT
  • Blacktown Hospital, NSW
  • Calvary Mater Newcastle Hospital, NSW
  • Royal North Shore Hospital, NSW
  • Westmead Hospital, NSW
  • Gold Coast University Hospital, QLD
  • ICON Cancer Care, QLD
  • Royal Brisbane and Women’s Hospital, QLD
  • Princess Alexandra Hospital, QLD
  • Flinders Medical Centre, SA
  • Royal Adelaide Hospital, SA
  • Alfred Hospital, VIC
  • Barwon Health, VIC
  • Box Hill Hospital, VIC
  • St Vincent’s Hospital, VIC

PARTICIPANTS

120 newly diagnosed multiple myeloma patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant

CURRENT ENROLLMENT

81

STATUS

Recruiting